Cumberland Pharmaceuticals (CPIX) vs Genelux (GNLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed Genelux (GNLX) over the past year, gaining 108.7% versus a loss of 57.7%. Genelux is the larger company by market cap ($109.5 million vs $107.6 million), about 1.0 times the size, while Cumberland Pharmaceuticals is growing revenue faster (+17.6% vs +0.0%). Cumberland Pharmaceuticals converts more of its revenue into profit, with a net margin of -6.4% versus -401812.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPIX | GNLX |
|---|---|---|
| Share price | $7.18 | $2.42 |
| Market cap | $107.58M | $109.49M |
| 1-day change | -4.77% | -2.42% |
| YTD return | +80.40% | -44.50% |
| 1-year return | +108.72% | -57.69% |
| 5-year return | +167.91% | — |
| Forward P/E | 51.29 | — |
| EPS (TTM) | $-0.62 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.52M | $8.00K |
| Revenue growth (YoY) | +17.57% | 0.00% |
| Net income (latest FY) | $-2.84M | $-32.15M |
| Gross margin | 85.02% | — |
| Operating margin | -6.27% | -415175.00% |
| Net margin | -6.37% | -401812.50% |
| 52-week high | $9.28 | $8.54 |
| 52-week low | $1.85 | $2.29 |
| Distance from 52-week high | -22.63% | -71.65% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +678.10% |
| Average volume | 76.95K | 288.93K |
| Shares outstanding | 14.98M | 45.25M |
| Employees | 88 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed GNLX by 166.4 percentage points over the past year.
- Cumberland Pharmaceuticals is more profitable, keeping -6.4 cents of every revenue dollar as net income versus -401812.5 cents for Genelux.
- Cumberland Pharmaceuticals grew revenue faster in its latest fiscal year (+17.57% vs 0.00%).
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
CPIX vs GNLX FAQ
Which is bigger, Cumberland Pharmaceuticals or Genelux?
Genelux (GNLX) is larger, with a market capitalization of $109.49M compared with $107.58M for Cumberland Pharmaceuticals (CPIX).
Which stock has performed better over the past year, CPIX or GNLX?
CPIX returned +108.72% over the past 12 months, compared with -57.69% for GNLX (price return, excluding dividends). Past performance does not predict future results.
Are Cumberland Pharmaceuticals and Genelux in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.